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Normal hematopoiesis is tightly regulated by hematopoietic microenvironment/niche in bone 
marrow (BM) via direct hematopoietic cell-niche cell interaction and factors secreted by 
various types of cellular niches.  The BM niche consists of cells of mesenchymal cell origin 
including mesenchymal stem cells (MSCs) and progenitor cells (MPCs). Accumulated 
evidence suggests the important role of BM mesenchymal cell niche for the maintenance of 
normal hematopoiesis and leukemogenesis.  However, the exact role of different niche 
elements and the molecular mechanisms in leukemia development remain poorly defined. 
Knowledge is required for developing new therapeutic strategy to effectively treat the diseases. 
This thesis focuses on mesenchymal niche contribution to normal and malignant 
hematopoiesis, particularly, myeloproliferative neoplasms (MPN) and acute myeloid leukemia 
(AML). By using mouse models, multi-color flow cytometry, RNA-sequencing, 
transplantation and lineage tracing techniques, the thesis work has demonstrated the 
contribution of BM mesenchymal cell niche in the initiation of the myeloproliferative disease 
and progression of AML. The specific role of BM MSCs and laminin isoforms in AML 
progression and therapy response were studied. In addition, this thesis reports the features of 
native skin MSCs and their function in supporting normal hematopoietic and AML stem cells.   
In paper I, the instructive role of BM niches in MDS/MPN initiation is studied by using signal-
induced proliferation associated 1 (Sipa1) gene deleted mice (Sipa1-/-) that develop age-
dependent MPN. The loss of Sipa1 induces BM niche alterations prior to the disease onset, 
including biased differentiation of Sipa1-/- MSCs towards adipocytes and upregulated 
expression of pro-inflammatory genes (Il-6 and TGF-β). Concomitantly, hematopoiesis 
maintenance gene (Cxcl12, Angptl1, Kitl) expressions were reduced in Sipa1-/- BM MSCs and 
MPCs. Transplantation of Sipa1+/+ hematopoietic cells to young Sipa1-/- mice resulted in 
MDS/MPN development, supporting the causative role of Sipa1 deficient niche for the 
development of MDS/MPN.  
The role of BM MSCs and MPCs during progression of AML is reported in paper II. By 
transplanting MLL-AF9+ AML cells to immunocompetent mice, we showed dynamic niche 
alterations induced by AML cells. During AML development, frequency of BM MSC & MPC 
were increased while hematopoiesis gene (Kitl, Cxcl12, Angptl1, Nov and Igf1) expression in 
BM MPCs were down regulated in correlation to AML engraftment in BM. Moreover, the 
expression of pro-inflammatory gene (Il-6) is elevated following the AML progression. 
Specifically, BM primitive subset of MSC (Ebf2+) is altered by AML cells to generate more 
progenies including Ebf2-MSC, MPC and CD44+ cells in the leukemic niche. The depletion 
of Ebf2+ cells accelerated AML development, demonstrating the suppressive role of Ebf2+ 
MSCs in AML progression possibly by maintaining normal hematopoiesis.  
In this study, upregulation of laminin 4 (Lama4) in both MSC and MPC was observed. To 
further investigate the functional consequence of Lama4 during AML development, the Lama4 
(Lama4-/-) deficient mice were employed in paper III.  
 
We firstly studied the role of Lama4 in hematopoiesis regeneration following irradiation-
induced stress and observed impaired recovery of erythropoiesis and megakaryopoiesis in 
Lama4-/- mice. On the contrary, AML progression and relapse were accelerated post 
transplantation of MLL-AF9+ AML cells. Furthermore, the Lama4-/- MSCs promoted AML 
cell growth and confer AML stem cell chemoresistance to cytarabine (Ara-C) via providing 
more metabolic support to the AML stem cells (LSCs). Taken together, paper III shows critical 
role of Lama4 in hematopoiesis recovery following irradiation and during AML development.  
Recent study has shown that AML LSCs infiltrate extramedullary organ. Meanwhile, skin has 
been reported to contain MSC-like population although the characteristics are not well defined. 
In paper IV, we employed Ebf2-gfp transgenic mice to prospectively characterize skin MSC 
phenotypically and functionally at bulk and single cell level. Skin Ebf2+ cells represent 
purified MSC while the Ebf2- fraction contained more differentiated MSCs that can be 
generated by the Ebf2+ cells, revealed by the in vivo lineage tracing of Ebf2+ MSCs.  
Both skin Ebf2+ cells and Ebf2-MSC displayed hematopoiesis supportive function, similar to 
their BM counterpart. Furthermore, co-culture of AML and AML CAFC on skin Ebf2+ and 
Ebf2-MSCs showed that skin MSCs also supported normal HSCs and provided 
chemoprotection for AML LSCs. In skin tissue of AML mice, infiltration of AML cells was 
observed and remained in skin tissue after Ara-C treatment, suggesting a possible contribution 
of skin MSCs to the persistence of AML cells. The skin Ebf2+ were found to be reduced in 
AML mice. However, the functional consequence of the skin MSCs remains to be investigated 
in the future. Altogether, paper IV reports skin harbors Ebf2+ and Ebf2-MSC with similar 
characteristics to BM MSC. Both skin Ebf2+ and Ebf2-MSCs support normal HSC and AML 
cells. Importantly, skin MSCs provide chemoprotection for AML LSC. 
In conclusion, the work in this thesis shows the role of BM niche for the initiation and 
progression of the myeloid malignancies using several transgenic mouse models. The work 
also provides evidence for critical role of Lama4 in hematopoiesis recovery following 
irradiation and AML progression. Furthermore, the biological features of skin MSCs and their 
function in supporting normal hematopoietic and AML cells. During Ara-C treatment, skin 
MSCs also displayed protective role for AML LSCs, indicating skin MSC possible role as a 
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Hematopoiesis is one of the important process in physiological systems that ensures sufficient 
blood cell production throughout life. After birth, hematopoiesis occurs primarily in the bone 
marrow (BM) where the hematopoietic stem and progenitor cells (HSPCs) interact with their 
microenvironment (niche). In BM, HSPCs are organized in well-controlled hematopoietic 
developmental hierarchy and they are responsible for the generation and the maintenance of 
hematopoiesis via their balanced self-renewal and differentiation capacity. The processes are 
tightly regulated by BM niche via direct cell-cell/matrix interactions and factors secreted by 
the stromal cells as well as intrinsic molecular pathways triggered by the signals from the niche. 
The niche is spatial location in BM consisting of heterogeneous niche components, 
extracellular matrix (ECM) and cytokines that regulates hematopoiesis extrinsically. In steady 
state hematopoiesis, the loss of niche cells impairs hematopoiesis mostly due to reduction of 
HSPC in BM (Mendez-Ferrer et al., 2010). Genetic aberration in niche may initiate 
development of malignant myeloid lineage cells that result in myeloid neoplasm (Hoggatt et 
al., 2016; Mendez-Ferrer et al., 2020). On the other hand, genetic mutation or rearrangement 
in hematopoietic cells such as translocation of MLL to AF9 (MLL-AF9) transforms 
hematopoietic cells intrinsically to clonally proliferated leading to acute myeloid leukemia 
(AML) at expense of normal hematopoietic cells.   
With recent advance in mouse modeling of hematopoiesis, multicolour flow cytometry (FACS) 
and single cell analysis, different niche cells have been identified based on cell surface markers, 
allowing further studies on specific niche cell contribution to normal and malignant 
hematopoiesis. One cellular compartment in BM niche is mesenchymal stem and progenitor 
cells (MSPCs) which remain heterogenous and consist of a small fraction of mesenchymal 
stem cells (MSCs) and mesenchymal progenitor cells (MPCs). There is increasing evidence 
about the role of MSPC in normal and malignant hematopoiesis  (Mendez-Ferrer et al., 2010; 
Omatsu et al., 2010; Raaijmakers et al., 2010; Schepers et al., 2013). However, the niche 
regulation is complex and dynamic. So far, the exact contribution and molecular mechanism 
of MSC and MPC during leukemogenesis and leukemia progression remain largely unknown.  
The focus of this thesis is to understand the contribution of MSC and MPC to normal and 
malignant hematopoiesis. By employing several advanced transgenic mouse models, FACS, 
global gene expression analysis, transplantation and state-of the art co-culture system, the role 
of BM MSC and MPC during the initiation and progression myeloid malignancy were 
evaluated. In addition, unlike BM MSC, the MSCs in extramedullary organs such as skin tissue 
have not been well characterized and their function for hematopoiesis has been ignored. This 
thesis further extends to study the characteristics of skin MSC as extramedullary AML site and 
provides evidence for the role of skin MSCs in supporting HSCs and AML-initiating stem cells. 





2 LITERATURE REVIEW 
2.1 HEMATOPOIETIC CELL LINEAGE HIERARCHY   
The mature blood cells are generated from hematopoietic stem cells (HSCs) through a well-
orchestrated developmental hierarchy where the rare primitive HSC population act as the cell 
source for replenishing all the short-lived mature blood cells. Adult HSCs are quiescent, self-
renewal and have capacity to generate different types of blood lineages (Cheshier et al., 1999; 
Morrison and Weissman, 1994). These cells can be identified based on their unique antigen 
profile. In mouse hematopoietic system, HSCs do not express mature hematopoietic marker 
(LIN-) such as CD3, CD4, CD8, B220, GR-1, NK1.1 and erythroid marker TER119, but 
express KIT and SCA1 (LSK) (Morrison et al., 1995).  HSCs consist of long-term (LT) HSC, 
short term (ST) and lymphoid primed multipotent progenitor (LMPP).  LT-HSC is 
phenotypically defined as LSKCD150+ while ST-HSC and LMPP are defined as LSKFLT3-
CD34+ and LSKFLT3+CD34+, respectively (Adolfsson et al., 2001; Christensen and 
Weissman, 2001; Kiel et al., 2005; Yang et al., 2005). Recent studies using single cell analysis 
have revealed the heterogeneity of BM HSCs and proposed a revised developmental pathway 
of HSCs with distinct lineage biased differentiation potency (Carrelha et al., 2018). The 
generation of almost all mature blood cells follows the hierarchical differentiation process 
where HSCs can first differentiate to hematopoietic progenitor cells (HPCs) with limited self-
renewal capacity, then lineage restricted progenitors and corresponding mature blood lineages 
(Figure 1).  
Figure 1.  Murine hematopoietic cell hierarchy. All blood lineages are generated from Hematopoietic stem 
cell (HSCs). 
HPCs contain common myeloid progenitor (CMP) and common lymphoid progenitor (CLP). 
CLP is phenotypically defined as Lin-IL7R+Thy1.1-SCA1lowKITlow and give rise to lymphoid 
cells (T, B and NK cells) (Fathman et al., 2011; Kondo et al., 1997). On the other hand, the 




In the hematopoietic lineage hierarchy, the CMP give rise to granulocyte monocyte progenitor 
(GMP, LIN-SCA1-KIT+CD34+CD16/32+) and megakaryocyte erythroid progenitor (MEP, 
LIN-SCA1-KIT+CD34low/-CD16/32-) which can be distinguished based on CD16/32 and CD34 
expression(Akashi et al., 2000). The GMP is terminally differentiate to granulocyte 
(CD11b+GR-1+) and monocyte (CD11b+) which can further differentiate to macrophage. The 
MEP is a precursor for erythrocytes (TER119+) and megakaryocyte (Mk, CD41+). 
Megakaryocytes further undergo maturation to produce platelet. Beside CMP, HSC is also 
able to generate MEP directly (Pronk et al., 2007). 
2.2 BONE MARROW (BM) NICHE 
The major anatomical location for hematopoiesis in adult is bone where HSCs reside and 
function to maintain hematopoiesis. In bone, HSCs preferentially locate at endosteal region 
with higher potency in comparison to HSPC in central marrow (Grassinger et al., 2010; 
Haylock et al., 2007). The specialized microenvironment surrounding HSCs is proposed as 
HSC niche which is not only an anatomical location of the cells but also a functional unit for 
regulating HSC activities (Scadden, 2006) (Figure 2). There are various cellular niche 
components and the factors produced by them.  
There are two major proposed niche types in bone, initially, the endosteal niche with bone 
lining osteoblasts as major niche cells and vascular niche with endothelial cells lining in 
sinusoidal vessels and arterioles as the cellular niche component (Itkin et al., 2016). 
Furthermore, many other cell types have been demonstrated to act as cellular niche elements 
for HSCs in mice. This includes MSCs and MPCs as well as adipocytes and osteocytes 
(Hoggatt et al., 2016; Le et al., 2018). In addition, several types of the cells of hematopoietic 
origin including megakaryocytes and macrophages were reported to be a cellular niche for 
HSCs. Mks regulates HSC quiescence via TGFb1, CXCL4 and TPO (Bruns et al., 2014; 
Nakamura-Ishizu et al., 2014; 
Zhao et al., 2014). Following 
myelosuppression, Mks migrate 
to blood vessels and promote 
HSC expansion through FGF1 
to recover the hematopoiesis 
(Zhao et al., 2014). The 
macrophages in BM (CD169+) 
promotes retention of HSPC 
and late erythroid maturation 
(Chow et al., 2013; Chow et al., 
2011).  
 
       Figure 2  Illustration of mouse BM niche (by Huan Cai, 2020). 
This thesis review mainly focuses on the niche cells of mesenchymal cell origin 
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2.3 CELLULAR COMPARTMENT OF BM MESENCHYMAL NICHE & ROLE IN 
HEMATOPOIESIS AT STEADY STATE  
2.3.1 Mesenchymal Stem Cell (MSCs) 
In BM niche, at steady state, MSCs are mostly distributed at endosteal sites. Phenotypically 
mouse BM MSC is defined as population with no expression hematopoietic marker (CD45-
TER119-), EC marker (CD31+) and CD44, but expressing CD51, CD140a/PDGFRA (PαS) 
and SCA1 (Morikawa et al., 2009; Pinho et al., 2013; Qian et al., 2013; Qian et al., 2012). 
Functionally, MSCs are characterized as cells with ability to form CFU-F and differentiate 
toward multiple mesenchymal lineages osteogenic, adipogenic and chondrogenic cells at bulk 
or single cell level (Qian et al., 2013; Sacchetti et al., 2007). Several markers including nestin, 
leptin receptor, Prx1 were shown to be expressed in MSPCs enriched with MSCs and MPCs. 
Some fraction of Nestin+ cells in BM display MSC characteristics although the CFU-F 
frequency is as low as 1/130 (Mendez-Ferrer et al., 2010). Depletion of the Nestin+ cells in 
BM leads to HSC dislocation (Mendez-Ferrer et al., 2010).There are 2 subsets of Nestin+ cells 
in BM which are Nestinbright at pre-arteriolar and Nestindim at sinusoidal in central marrow and 
decorated with sympathetic nerves and schwann cells. The expression of hematopoiesis 
supportive genes (Cxcl12, Kitl, Angptl1) is higher in Nestinbrightcells (Kunisaki et al., 2013). 
The numbers and the function of Nestin+ cells to maintain HSPC in BM are regulated by 
transcription factor Snai2 that suppresses Spp1, the negative regulator of hematopoiesis (Wei 
et al., 2020).  
Early B-cell Factor 2 (Ebf2) is uniquely expressed in non-hematopoietic and non-endothelial 
cells and the Ebf2-expressing cells in mouse BM are highly enriched with primitive MSC 
expressing SCA1, CD51 and CD140a (Qian et al., 2013). There is about 60% of Ebf2+ cells 
lowly expressing Nestin. In mouse BM, the Ebf2+ cells are in quiescence, located mostly at 
endosteal sites with MSC characteristics and can generate more differentiated Ebf2- 
mesenchymal cells indicating Ebf2+ cells are primitive MSC and contribute to mesenchymal 
cell turnover. Perturbation of Ebf2 expression reduces HSC in adult mice (Kieslinger et al., 
2010). 
2.3.2 Mesenchymal Progenitor Cells (MPCs)  
Similar to MSC, MPCs are found in non-hematopoietic and endothelial fraction (CD45-
TER119-CD31-), do not express CD44 but express CD51 and CD140a (Schepers et al., 2013). 
The phenotypic difference between MSC and MPC is SCA1 expression. While MSCs are 
SCA1+, the MPC do not express SCA1. MPCs have been studied in different transgenic mouse 
models that bring different terminology for referring MPC, as discussed below.  
CAR (Cxcl12-abundant reticular cells). The terminology comes from study that employs 
CXCL12-GFP transgenic mice. CAR cells are MPC and distributed in sinusoid area  
(Sugiyama et al., 2006). CAR highly express Cxcl12 and Scf for maintaining HSPC (Ding and 




This feature and their immunophenotype have been validated by single cell sequencing of the 
BM stromal cells (Baccin et al., 2020; Baryawno et al., 2019). BM CAR cells have potency to 
generate both adipocytes and osteoblasts and depletion of the cells abrogates HSPC 
maintenance and promotes myeloid differentiation (Omatsu et al., 2010). In CAR, 
transcription factor Foxc1 is critical for regulating HSPC niche formation since loss of Foxc1 
increases adipogenesis and reduces BM HSPC phenotypically and functionally. In addition, 
expression of Cxcl12 and Scf are also downregulated when CAR cells lose Foxc1 (Omatsu et 
al., 2014). CAR cells in BM express transcription factor early B-cell Factor 3 (Ebf3). Ebf3 
expression in CAR controls the osteogenic differentiation, contribute to expression of Cxcl12 
and Scf as well as maintaining number of LT-HSC, MEP, GMP and pro-E (Seike et al., 2018). 
LepR (Leptin Receptor+) cells are highly overlapping with CAR cells or mainly are SCA1-
MPC (Zhou et al., 2017). Specific loss of Cxcl12 in LepR+ cells does not alter HSC (Asada et 
al., 2017). Following irradiation, expression of Scf in LepR+ cells plays important role in 
hematopoiesis recovery in mice (Zhou et al., 2017).  
2.3.3  Osteoblast & Adipocyte  
Osteoblasts are bone forming cells located at endosteal site. Osteoblasts maintain HSC 
frequency via Notch signaling by expressing Notch ligand jagged 1 (Jag1) for HSC (Calvi et 
al., 2003). The expression of Cxcl12 in osteoblast is required to maintain CLPs, but is 
dispensable for HSC maintenance (Ding and Morrison, 2013). Ablation of osteoblast causes 
reduction of HSC frequency at quiescence state and impairs HSC self-renew properties as 
reflected by impaired hematopoiesis reconstitution in secondary transplantation (Bowers et al., 
2015). In contrast to osteoblast, BM adipocytes is a negative regulator for hematopoiesis 
maintenance as increased adipocytes reduces frequency and function of HSPC (Naveiras et 
al., 2009). 
2.3.4 Endothelial cell (EC) & Sympathetic nervous system (SNS) 
BM EC consists of arteriolar and sinusoidal EC (Itkin et al., 2016; Kusumbe et al., 2014). 
Arteriolar ECs are distributed in trabecular area, central marrow and close to endosteal area. 
In central bone (marrow), the large unbranched arteries are wrapped with α-SMA while the 
arteries close to endosteal area branches to small arteriole with high expression of CD31 and 
Endomucin (EMCN). The CD31highEMCNhigh ECs are located closely to endosteal site and 
mediate growth of bone vessel (Kusumbe et al., 2014). The sinusoids are mostly distributed in 
central marrow and express low CD31 and EMCN (Kusumbe et al., 2014). Compared to the 
artery, sinusoid ECs are leaky which is a suitable trafficking site of HSPCs. The arteriolar ECs 
support quiescence HSC with low ROS level (Itkin et al., 2016). Arteriole in BM is decorated 
with sympathetic nervous system (SNS) that also contribute to hematopoiesis via β3-
adrenergic receptor (Mendez-Ferrer et al., 2008). 
In arteries, there are a subset of Apelin (Apln+) ECs which co-express EMCN, CD31, VE-
cadherin, VEGFR2 and VEGFR3.  Compared to other EC, Apln+ EC is highly enriched with 
gene for sprouting angiogenesis and VEGFR signaling. Depletion of Apln+ EC reduces 
frequencies of CLP, CMP and HSC in BM as well as impairs HSC function to reconstitute 
hematopoiesis (Chen et al., 2019).  
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BM EC has been reported to maintain HSC through E-selectin and Jag1. The interaction of 
vascular E-selectin with HSCs is critical for maintaining HSC quiescence and preserve HSC 
from 5-FU injection (Winkler et al., 2012). Furthermore, loss of Jag1 decreases LT-HSC 
phenotypically and functionally as LT-HSCs become more cycling (Poulos et al., 2013). 
Recently, single cell mapping of BM niche cells revealed the expression of other Notch ligands 
(Dll1 & Dll4) in BM ECs. The abrogation of Dll4 in ECs decreases CLP frequency while the 
myeloid progenitor increases (Tikhonova et al., 2019). In addition to Jag1, BM EC also 
express Cxcl12 which has been shown to be important for maintaining BM HSC (Ding and 
Morrison, 2013). 
 
2.4 EXTRACELLULAR MATRIX (ECM) IN BM NICHE  
In HSC niche unit in BM, besides HSCs and the niche cells, extracellular matrix proteins 
(ECMs) such as fibronectin, collagen type I, III, IV, osteopontin, laminin, nidogen and 
tenascin-c are a big family of molecular niche components (Balzano et al., 2019; Nakamura-
Ishizu et al., 2012; Nilsson et al., 1998). Existence of extracellular matrix (ECM) not only 
provides integrity, but also regulating hematopoiesis. HSC anchorage to Collagen type I via 
calcium-sensing receptor enhances CXCR4 signal for HSC retention (Adams et al., 2006; Lam 
et al., 2011). The anchoring of HSPC to osteopontin in BM niche via β1 integrin (α9β1 and 
α4β1) and CD44 play a role in HSC migration and retention (Grassinger et al., 2009). 
Osteopontin regulates hematopoiesis in a negative manner since it suppresses the HSC 
expansion (Stier et al., 2005). Tenascin-C also involves in regulating hematopoiesis. At 
steady state, loss of tenascin-C reduces colony forming capacity while the BM cell number 
and structure are maintained (Nakamura-Ishizu et al., 2012; Ohta et al., 1998). Furthermore, 
following myelosuppression, tenascin-C expression in CD31+ and MSPC are upregulated and 
enhance HSPC proliferation cooperatively with fibronectin to reconstitute hematopoiesis 
(Nakamura-Ishizu et al., 2012). 
Laminin 
Laminin is a heterotrimeric glycoprotein in basement membranes of endothelial cells, skeletal 
muscles and developing kidney (Scheele et al., 2007). There are 18 different isoforms of 
laminins described based on heterotrimeric combination of α, β and γ chain. In BM, the blood 
vessels express different laminin chains including laminin α4 chain which is bound via integrin 
α6. The integrin α6 is widely expressed on HSCs and facilitates HSC migration as well as 
proliferation (Gu et al., 2003; Qian et al., 2006; Susek et al., 2018). However, the role of 
Lama4 in malignant hematopoiesis has not been reported.  
 
2.5 BM NICHE IN MYELOID MALIGNANCY  
Myeloid malignancy (neoplasia) is a group of diseases with perturbed myelopoiesis due to 
gene alterations related to proliferation, differentiation or self-renewal. Based on 2016 revision 
to the WHO classification (Arber et al., 2016; Barbui et al., 2018) myeloid neoplasm can be 
categorized into chronic myeloid neoplasms and acute myeloid leukemia (AML).  
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The chronic myeloid neoplasms include (1) myeloproliferative neoplasms (MPN), (2) 
myelodysplastic syndromes (MDS), (3) MDS/MPN (CMML, aCML, MDS/MPN with 
ringsideroblast &thrombocytosis and JMML), and (4) myeloid / lymphoid neoplasms with 
eusinophilia and rearrangement of PDGFRA, PDGFRBB and FGFR1 or PMC1-JAK2. MPN 
could be further classified based on presence of Philadelphia chromosome (BCR-ABL1). The 
BCR-ABL1+ MPN is defined as chronic myeloid leukemia (CML) while BCR-ABL1- MPN 
is further categorized into polycythemia vera (PV), essential thrombocythemia (ET), chronic 
neutrophilic leukemia (CNL) and primary myelofibrosis (PMF).  
The niche contribution to myeloid malignancies have been increasingly recognized. Studies 
with mouse models have provided evidence for the role of BM niche in the pathogenesis of 
the diseases (Hoggatt et al., 2016). Mice with deletion of Signal-induced proliferation-
associated gene-1 (Sipa1), a negative regulator in G-protein signaling, is reported to 
develop age-dependent myeloproliferative disorders resembling human CML at chronic and 
blast crisis, anemia and MDS (Ishida et al., 2003; Kometani et al., 2006). Furthermore, 
activation of BCR-ABL1 reduces Sipa1 expression and increases frequency of LSK in spleen 
in mice (Kometani et al., 2006). However, it is not clear whether the disease is initiated by 
loss of Sipa1 in hematopoietic cells or in BM niches. Nevertheless, the long latency of the 
disease increases the possibility of clonal evolution of hematopoiesis in the Sipa1-/- mice, thus, 
make the mice serve as a good model to study the potential contribution of BM niche to the 
MPN development.  
 
2.5.1 The instructive role of BM niche myeloid neoplasm 
2.5.1.1 Dicer1 perturbation in osteoprogenitor promotes MDS  
By using Osx-GFP-Cre+Dicerfl/fl to delete Dicer1 in osteoprogenitor cells, Raaijmakers et al. 
2010 demonstrated the role of osteoprogenitor in the development of MDS (Raaijmakers et 
al., 2010). The osteoprogenitor lacking Dicer1 reduces osteogenic differentiation as 
represented by decreased alkaline phosphatase and calcified deposition in vitro and declined 
mature osteoblast expressing osteocalcin in vivo. However, loss of Dicer1 does not reduce 
bone volume. Besides alteration in osteogenesis, Dicer1-deficient osteoprogenitor cells 
increase HSC proliferation and impair Mk differentiation. The induced MDS is manifested by 
leukopenia, profound anemia & thrombocytopenia, splenomegaly, increased myeloid 
frequency and dysplastic megakaryopoiesis. The causative role of Dicer1 deficient niche in 
the disease development was confirmed by transplantation of normal hematopoietic cells in 
the Osx-GFP-Cre+Dicerfl/fl mice. In addition to bone defects, Dicer1 deletion also results in 
reduction of Shwachman-Diamond-Bodian syndrome (Sdbs), the gene mutated in patients 
with SDBS and predisposition to leukemia development (Boocock et al., 2003). This study for 
the first time proposed the instructive role of a specific BM niche cell population in the 
initiation of myeloid malignancies. However, the mechanism underlying the malignant 




2.5.1.2 Mutation of protein tyrosine phosphatase (Ptpn 11) in MSPCs drives MPN 
Ptpn11 is gene encoding protein tyrosine phosphatase Shp2. The mutation of Ptpn11 has been 
identified in juvenile myelomonocytic leukemia (JMML), a childhood MDS/MPN, and in 
childhood AML (Tartaglia et al., 2004). A recent study has reported that activating mutation 
of Ptpn11 (Ptpn11E76K+) in MSPCs, not differentiated osteoblasts promotes the development 
of MPN in mice via abnormal production of pro-inflammatory cytokines (IL-1β & Ccl3) in 
BM (Dong et al., 2016). The phenotypes are manifested by increased frequency of myeloid 
cells in BM and spleens with evidence of splenomegaly. The recapitulation of MPN-like 
phenotype is accompanied by increased apoptotic LT-HSCs (LSKCD150+ cells). The high 
level of CCL3 attracted inflammatory myeloid (CD115+Gr1+) to BM where HSC reside in the 
Ptpn11E76K+ mice, subsequently led to HSC activation and displacement from its mesenchymal 
niche. Administration of CCL3 receptor antagonist could reverse the MPN phenotypes in 
Ptpn11E76K+ mice. The findings show evidence for important contribution of BM 
microenvironment to the pathogenesis of MPN. 
In addition, activating b-catenin mutation in BM osteoblasts (Kode et al., 2014) and loss of 
Notch signaling in BM ECs (Wang et al., 2014) could induce malignant transformation of 
hematopoietic cells, providing additional evidence for the impact of specific genetic 
manipulation of osteoblasts and ECs for the development of myeloid malignancies including 
AML. 
 
2.5.2 Remodeling of BM niche in myeloid malignancies  
2.5.2.1   Nestin+ cells in Jak2(V617F) mutated MPN mice & Niche remodeling in CML 
mouse model 
It has been shown that the role of BM niche is stage-specific (Lane et al., 2011). Once leukemia 
is established, the BM niche can be altered by the malignant hematopoietic cells and render 
the niche more supportive for the malignant cell growth but detrimental for normal 
hematopoiesis (Behrmann et al., 2018; Hoggatt et al., 2016; Schepers et al., 2013). The 
induction of MPN by transplanting JAK2-V617F cells into normal recipient mice result in 
alteration of Nestin+ cells, increased fibrosis and bone formation (Arranz et al., 2014). The 
Nestin+ cell frequency and ability to form colony are reduced due to induced apoptosis. 
Molecular profiling shows that Nestin+ cells in MPN mice show reduced expression of genes 
related to HSC maintenance and MSC characteristic. Nestin+ cells have been shown to be 
important niche component for HSCs (Mendez-Ferrer et al., 2010). In line with this, depletion 
or reduction of Nestin+ cells could cause further reduction of HSCs and accelerates MPN 
progression. The decreased frequency of Nestin+ cells results from schwann cell death induced 
by activation of JAK2 (V617F) mutation and elevation of IL-1 in mutant hematopoietic cells 
in MPN BM. Administration of neuroprotective drug inhibits MPN progression by preventing 
loss of Schwann cells and Nestin+ cells.  
The niche-remodeling effects were also observed in a CML mouse model (Schepers et al., 
2013). CML engraftment in BM results in expansion of MSC and osteoblast progenitor cells 
in BM and increased level of CCL3, THPO and G-CSF in BM plasma of MPN mice.  
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The altered niche factors including upregulated inflammatory cytokines and cellular niche 
composition in turn promote MPN progression in the mice, providing a molecular and cellular 
evidence for creation of self-reinforcing leukemic niche and new insight into new strategy in 
therapeutic intervention of CML. 
2.5.2.2 BM niche & AML 
The niche regulation is disease type specific as shown previously in CML and AML (Krause 
et al., 2013), making it imperative to study the specific niche contribution to AML 
development and treatment response. AML is heterogenous myeloid malignancy originated 
from immature progenitor cells with genetic disorders. AML could develop as de novo AML 
and secondary AML following chronic stage of myeloid neoplasm (Lindsley et al., 2015).  
Mixed Lymphoid Leukemia (MLL) rearrangement with translocation partner gene is common 
genetic disorder in AML. One of translocation partner gene is AF9 (Meyer et al., 2018). 
Rearrangement of MLL provide proliferative advantage and self-renewal properties in AML 
cell through enhancement of HOX genes (Li et al., 2009). Most common drugs for AML 
treatment are cytarabine (Ara-C) and danorubicin (Buchner et al., 2012). Depending on 
phenotypes of AML, targeted therapy can be administered. FLT3 inhibitor (midostaurin) is 
administered for FLT3 (FLT3-ITD) mutated AML or Enasidenib for IDH2 mutated AML 
(Wei and Tiong, 2017). Another therapeutic drug is BCL2 inhibitor (venetoclax) which acts 
on mitochondrial activity of AML cells (Scheffold et al., 2018; Wei and Tiong, 2017).  
However, the treatment outcome for AML patients has not been much improved in last 
decades. Current challenge for treating AML therapy is poor survival of patients, in 
particularly in elderly patients (> 60 years old) which only has 5%-15% survival within 5 years 
(Burnett et al. 2011). The short survival is mainly due to AML relapse from residual AML 
stem cells (LSCs) (Bonnet and Dick, 1997; Shlush et al., 2017). Therefore, there is urgent 
need to develop new treatment strategy for AML. 
Similar to the finding in CML blast crisis, the AML induced BM niche alterations including 
expansion of MPCs with dysregulated functionality have been demonstrated in mice. This 
might be associated with progressive loss of normal hematopoiesis and AML progression since 
the critical niche factors for maintaining normal HSCs were dysregulated and reduction of 
HSPCs were observed (Baryawno et al., 2019; Hanoun et al., 2014) 
In AML mice, BM ECs are increased but become hypoxic and leaky due to increased nitric 
oxide production as NOS3 is activated in Nox4 highly expressed AML EC (Passaro et al., 
2017). The endosteal vessels are progressively reduced accompanied by elevated production 
of anti-angiogenic (CXCL2) and pro-inflammatory TNF (Duarte et al., 2018). Perturbation of 







Besides the vascular alterations, the mature osteoblasts and bone volume of AML mice are 
reduced (Duarte et al., 2018; Hanoun et al., 2014), resulting in loss of LT-HSCs. On the other 
hand, constitutively activating β-catenin signal in osteoblast leads to genetic mutation in LT-
HSC and AML development (Kode et al., 2014). Perturbation of FoxO1 in osteoblast with 
constitutive β1-catenin signal prevents the AML development (Kode et al., 2016). Impaired 
hematopoiesis supportive function also occurs in other cell population in hematopoiesis niche.  
2.5.3 BM niche in chemoprotective function of leukemic cells  
2.5.3.1 Cell adhesive interactions of leukemic cells with their niche in chemoprotection  
In AML mice, the BM CD31+ cells upregulate E-selectin while AML cells increase binding 
to E-selectin (Barbier et al., 2020). The E-selectin binding facilitates survival of AML cells 
through AKT and NF-κB signaling pathway. Blocking E-selectin binding in combination with 
chemotherapy (Ara-C + Doxorubicin) prolongs survival of AML mice.  
AML cells have been reported to express integrin such as α4β1 integrin (VLA-4) while BM 
niche consists of ligands for the integrin, such as fibronectin. Such interaction during 
danorubicin or Ara-C administration to AML cells increases AML cell survival (Matsunaga 
et al., 2003). The VLA-4 mediated interactions with EC also provides survival advantage for 
AML cells (Poulos et al., 2014). 
2.5.3.2 BM niche & metabolic preference of AML LSCs 
Similar immunophenotypes and quiescence characteristics of HSC and LSC create a challenge 
to target LSC specifically. The metabolic preference, on the other hand, is different between 
HSC and LSC (Farge et al., 2017; Simsek et al., 2010). For maintaining self-renewal, HSCs 
depend on anaerobic glycolysis while oxidative phosphorylation (OXPHOS) in mitochondria 
is repressed (Simsek et al., 2010). In contrary, AML LSCs rely on OXPHOS for survival and 
during chemotherapy (Farge et al., 2017). Along with OXPHOS activity, elevation of fatty 
acid metabolism, fatty acid receptor (CD36) expression and reactive oxidative species (ROS) 
production are also detected in AML LSCs.  Impaired OXPHOS in AML LSC prolongs 
survival of AML mice due to increased oxidative stress leading to apoptosis (Baccelli et al., 
2019). Recent study reports BM Nestin+ cells mediate the elevation of OXPHOS in AML cells 
via mitochondria transfer that also enhances AML antioxidant defense (Forte et al., 2020).  
2.5.4  Extramedullary site provides chemoprotection for LSCs 
The presence of CD36+ CML LSCs have been reported in gonadal white adipose tissue (WAT) 
in mice (Ye et al., 2016). In blast crisis CML that resembles AML mouse model (Ye et al., 
2016), the infiltrated AMLs in gonadal WAT use fatty acid metabolism and remain in 
quiescence. The CD36+ LSCs could escape therapeutic agents and are preferentially retained 





2.6 MESENCHYMAL NICHE IN EXTRAMEDULLARY ORGAN 
The infiltration of AML LSCs in gonadal WAT indicates leukemic niche may exist at 
extramedullary sites in addition to BM and spleen. Furthermore, presence of mesenchymal-
like population such as early adipocyte progenitor cells with similar characteristics to BM 
MSC (Ambrosi et al., 2017; Festa et al., 2011; Rivera-Gonzalez et al., 2016; Rodeheffer et al., 
2008) suggests AML LSCs might receive hematopoiesis support from MSC-like population 
at extramedullary sites.   
Skin is other extramedullary organ containing dermal adipose tissue and mesenchymal-like 
population. Skin-derived precursor cells are multipotent adult stem cell population in skin with 
Nestin expression and able to form sphere-forming cells in cultivation with EGF and FGF 
(Toma et al., 2001; Toma et al., 2005). Although the existence of MSC-like population is 
reported in skin tissue (Kimlin and Virador, 2013; Vaculik et al., 2012), the true identity and 
biological properties of skin MSC remain unknown since the cultivation method for selecting 
the mesenchymal stromal cells alters the native characteristics of the cells (Jones and Schafer, 
2015; Qian et al., 2012). In addition, lack of knowledge of skin MSC natural phenotype hinders 
further study to evaluate the role of mesenchymal niche in skin tissue for the growth of the 
infiltrated leukemic cells and their response to chemotherapy.  
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3 RESEARCH AIMS 
The present study aims to investigate mesenchymal niche contribution to normal and malignant 
hematopoiesis with focuses on myeloid malignancy including MDS/MPN and AML   
 
Paper I  
To evaluate the role of BM niche in the initiation of MDS/MPN using Sipa1-/- mice 
 
Paper II  
To investigate BM niche-remodeling dynamics in AML and the specific contribution of BM 
MSC to AML progression.   
 
Paper III  
To evaluate the role of Laminin α4 chain in hematopoiesis regeneration during hematopoietic 
stress and chemotherapy response 
 
Paper IV  
To prospectively characterize skin MSCs and explore their function in normal hematopoiesis 






4 MATERIALS AND METHODS  
To address the research questions, we have employed a list of transgenic mouse models and 
advanced technologies including sequencing, lineage-tracing, confocal imaging, in vivo and in 
vitro stem cell assays. In this section, advantages and limitations of selected methodological 
approaches are discussed. The detailed descriptions of the methods are presented in the original 
papers (Paper I – IV). 
4.1 MOUSE-MODELLING OF HEMATOPOIESIS  
Mouse modelling has been widely used in the field of normal and malignant hematopoiesis due 
to both biological similarities between mice and human and ethical reason. Our studies have 
mainly used mice with C57BL/6J background since most of the previous studies on 
hematopoiesis have been done on this mouse strain, which makes it possible for us to apply 
and compare previous findings with our results. However, the Ebf2-Egfp transgenic reporter 
mice (in paper II and paper IV) with FVB/N genetic background were used for studying the 
role of Ebf2-expressing MSCs for AML development and characterizing skin MSCs. Here, to 
avoid graft-versus host/leukemia effects, the AML cells used for transplantation were 
generated on the same background. In addition, we were aware of strain-specific difference in 
immunophenotype (such as CD34 and CD90) of the mesenchymal stroma cells (Peister et al., 
2004), thus, we have chosen the MSC-markers that are expressed in MSCs from mice of 
different mouse background.  
FVB/N and C57BL/6J genetic background have different haplotype of Ly-6 locus which are 
Ly6a (Ly6E.1) and Ly6b (Ly6A.2), respectively (Jurecic et al., 1993; Spangrude and Brooks, 
1993). The frequency of SCA1+ in BM LIN- is lower in Ly6a mouse than Ly6b (Spangrude and 
Brooks, 1993). Furthermore, the BM mesenchymal stroma of FVB/N mice have higher SCA1 
expression (Peister et al., 2004). In order to circumvent result bias due to the difference of 
genetic background, the present study was designed to allocate mouse strain with same genetic 
background between compared experiment.   
In paper II and IV, to analyze the in vivo function of Ebf2-expressing MSCs to AML niche 
formation and AML development, the Ebf2-gfp-CreERT2-Tomato mice and Ebf2-CreERT2-DTA 
mice with mixed genetic background of FVB/N and C57BL/6J were backcrossed to be on 
C57BL/6J background. 
In paper I and III, the mice with germline deletion of  Sipa1 and Lama4 (Sipa1-/- and Lama-/-
)  were used, respectively. To specifically study the niche impact on hematopoiesis, the paper 
I took advantage of reciprocal transplantation following irradiation. The irradiation induced 
effect on the host niche and radiosensitivity of the mice that might interfere experiment results 




4.2 INDUCIBLE CRE/LOXP SYSTEM & TAMOXIFEN EFFECT ON MOUSE 
HEMATOPOIETIC SYSTEM  
The inducible Cre/Lox P system driven by Ebf2 promoter enabled us to track or deplete Ebf2+ 
cells in Ebf2-gfp-CreERT2-Tomato and Ebf2-CreERT2-DTA mice in a spatial and temporal 
manner. By employing CreER variant (Feil et al., 1996), Cre recombinase is activated by 
tamoxifen (TAM) as TAM binds to the Estrogen receptor fused with Cre and translocates Cre 
to nucleus. The Cre recombinase subsequently recognizes the loxP sites that flanks STOP 
codon, resulting in activation of Tomato or DTA.  
To avoid high toxicity in hematopoietic cells, the present study employed lower dose (3mg – 
150mg/kg for 3 days) than reported toxic dose (175mg/kg for 5 days) of TAM (Higashi et al., 
2009). Furthermore, as 5mg tamoxifen hematological effects are reversible within 2 weeks 
(Uhmann et al., 2009), the subsequent experiments were performed approximately 4 weeks 
after the last tamoxifen injection in order to excluding the unspecific effects induced by TAM. 
In addition, for testing effect of MSC deletion on AML development, we also treated our 
control mice with TAM.  
 
4.3 PROSPECTIVELY NICHE CELL ISOLATION WITH MULTICOLOUR 
FLUORESCENCE ACTIVATED CELL SORTING (FACS)  
Since niche cell isolation based on in vitro culturing results in cell alteration phenotypically 
and molecularly (Jones and Schafer, 2015; Qian et al., 2012), the niche cells were 
prospectively isolated by FACS after enzyme dissociation. The niche cells isolated in present 
study were (1) MSC, (2) MPC and (3) EC (CD31+) cells. The BM MSCs and MPCs were 
sorted by excluding hematopoietic and endothelial cell (CD45-TER119-CD31-) prior selecting 
CD44- population. Further sub-fractionation was done based on SCA1 and CD51 expression. 
The BM MSC was phenotypically defined as CD45-TER119-CD31-CD44-SCA1+CD51+ 
while MPC was defined as CD45-TER119-CD31-CD44-CD51+SCA1-. For isolating MPN 
patient niche cells in paper I, the human MSC was sorted based on CD45-CD235-CD31-CD44- 
phenotypes while CD31+ cells were sorted based on CD45-CD235-CD31+ phenotypes. The 
MSC identity were usually confirmed by their capacity in forming CFU-Fs and in vitro 
expansion. The procedure is tedious since niche cells are rare in frequency. However, this will 
allow us to reveal the biological properties and true molecular profile of the cells.   
 
4.4 PROSPECTIVE CHARACTERIZATION OF MSC 
MSC was characterized based on (1) phenotypic analysis and (2) functional assays. The 
phenotypic analysis was performed based on phenotypically defined MSC (CD45-TER119-




4.4.1 Colony Forming Unit-Fibroblast (CFU-F) assay 
CFU-F assay was used to functionally evaluate MSCs by platting sorted MSC at single cell or 
low density in vitro. One CFU-F was defined if the colony consisted of 50 cells with 
fibroblastic morphology. It is important to note that each MSC should be able to form a CFU-
F, however, not all the CFU-Fs are MSCs unless it is can be serially re-plated in vitro and 
transplanted in vivo.  The CFU-F assays and in vitro expansion of MSC were performed in 
hypoxic condition which preserves multilineage properties and inhibits senescence of MSC 
(Tsai et al., 2011).  
4.4.2 In vitro multilineage differentiation assay  
MSCs in BM have potency to differentiate toward adipocyte, osteoblast and chondrocytes 
(Qian et al., 2013; Sacchetti et al., 2007). Thus, in vitro osteogenic, adipogenic and 
chondrogenic differentiation were performed to evaluate MSC function. In paper IV, 
chondrogenic differentiation was performed in both monolayer and micromass culture to 
validate the chondrogenic potencies of skin MSC. The chondrogenic differentiation was 
evaluated based on toluidine blue staining which visualizes the deposition of proteoglycan. 
For evaluating osteogenic differentiation, the formed mineralization was detected by alizarin 
red staining. The positive adipogenic differentiation was evaluated based on formation of lipid 
droplets that were stained by Oil-Red-O dye.   
 
4.5 MSC CHARACTERIZATION AT SINGLE CELL LEVEL  
In paper IV, in order to estimate self-renewal ability of skin MSC, single cell sorting of Ebf2+ 
and Ebf2-PaS cell were performed. Number of CFU-F generated from single cell sorting was 
counted to calculate frequency of MSC in skin Ebf2+ and Ebf2-PaS fraction. The Ebf2+ and 
Ebf2-PaS clones generated in the single cell CFU-F assays were sampled for in vitro serial re-
plating and multilineage differentiation assays. The frequency of the cell clone with 
multilineage potency and serial re-plating ability were considered to functionally define 
MSCs. 
 
4.6 IN VIVO LINEAGE TRACING OF EBF2+ CELLS 
Lineage tracing was conducted to trace Ebf2+ MSC and their role in the formation of leukemic 
niche in BM (paper II) and skin tissue homeostasis (paper IV). For tracing Ebf2+ cells, the 
Ebf2-gfp-CreERT2-Tomato mice were employed. Upon Cre activation by TAM injection at 
desired time point, Tomato became permanently expressed in the Ebf2+ cells and the cells 
generated from them. The GFP+Tomato+ cells long term post TAM injection should represent 
the Ebf2+ MSCs that were activated and maintained by being in quiescent state or self-




4.7 PHENOTYIC ANALYSIS WITH FACS  
FACS was utilized to phenotypically analyze the cells and sort the cells based on their cell 
surface markers for subsequent functional and molecular assays. The live cells were defined 
based on Propidium Iodide (PI-) or 7AAD-. The frequency of niche cells within total live cells, 
non-hematopoietic (CD45-TER119-) and non-endothelial (CD31-) stromal cells were quantify. 
FACS was also used to analyze cell cycle state, HSPC phenotypic analysis and AML 
engraftments (Paper II – IV). In paper II& IV, FACS was also employed to obtain frequency 
of Ebf2+(GFP+)Tomato+ cells and GFP-Tomato+ frequency in lineage tracing experiment.  
To achieve high quality results by FACS, several aspects should be considered: (1) For making 
the most of limited cell number, the multicolour FACS was performed by firstly creating the 
antibody panels based on FACS optical configuration and selected fluorochromes for allowing 
optimal fluorochrome signal separation. (2) Except cell cycle analysis, the phenotypic analyses 
were performed on freshly isolated mononuclear cells. For maintaining a good viability, cells 
were re-suspended in 5% - 10% serum. (3) During acquisition for sorting or analysis, 
Fluorescence Minus One (FMO) for each fluorochrome signal was used to define the positive 
or negative gating.  
 
4.8 IMMUNOFLUORESCENCE (IF) STAINING AND CONFOCAL IMAGING 
To localize cell distribution in tissue, IF and confocal imaging were performed. In paper III 
and IV, confocal imaging was employed to evaluate AML cell infiltration in BM and spleen. 
In paper IV, staining of vascular marker (CD31) was performed on dorsal skin tissue prior 
confocal imaging to distinguish circulating AML cells and infiltrated AML cells in dorsal skin 
tissue.   
For in vivo lineage tracing of skin Ebf2+ (paper IV), IF & confocal imaging were employed 
to define location and identity of skin Ebf2+ cells as well as their progenies (GFP-Tomato+). 
Thus, whole mount IF staining of vascular (CD31 or MECA32) and perivascular markers (a-
SMA, NG2 and Nestin) were performed. For evaluating anti-GFP antibody specificity, skin 
tissues from WT littermate were used. The setup of confocal microscopy configuration was 
done by using skin tissue from single transgenic mouse and secondary antibody staining 
control. Image processing and analysis were performed with NIS-element AR-analysis ver 
5.20.00 64-bit software (Nikon). 
 
4.9 SYNGENIC TRANSPLANTATION FOR ASSAYING HSC AND LEUKEMIA 
DEVELOPMENT  
Prior to transplanting BM cells, the recipient mice were either sub-lethally irradiated (6 Gy) or 
lethally irradiated to allow donor cells engraft in BM. The sub-lethally irradiation was 
performed in paper I with aim to preserve host microenvironment while enabling sufficient 
donor cell engraftment. The lethal irradiation impaired the function of niche cells although 
niche cells were anatomically present (Abbuehl et al., 2017; Friedenstein et al., 1981; 
Greenberger et al., 1996; Naparstek et al., 1986; Severe et al., 2019) 
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In paper I, transplantation of BM hematopoietic cells was performed to evaluate whether 
Sipa1 acted intrinsically or extrinsically in the development of MDS / MPN. To evaluate the 
extrinsic mechanism, BM CD45+ from Sipa1+/+ (WT) were injected to Sipa1-/- recipient mice 
while intrinsic mechanism was evaluated in reciprocal transplantation setting.  
In paper III, the lethally irradiation was performed on the Lama4+/+ and Lama4-/- mice that 
developed AML to eliminate AML and allow for maximal homing of the donor cells to mimic 
clinical therapeutic settings where patients undergo total body irradiation prior to 
hematopoietic cell transplantation. 
 
4.10 AML CELL TRANSPLANTATION TO GENERATE AML MOUSE MODEL 
To generate AML mouse model, MLL-AF9+ AML cells (Somervaille and Cleary, 2006) were 
intravenously injected to immunocompetent (non-irradiated) recipient mice. The recipient 
mice did not need to be irradiated due to the aggressiveness of MLL-AF9+ AML cells. The 
advantage of this setting is to maintain host niche integrity, providing an ideal model to study 
niche-remodeling by AML. This method was employed in paper II, III and paper IV. For 
visualizing AML cells in skin tissue (paper IV), bone marrow and spleens (paper III and 
IV), the MLL-AF9+ AML cells with b-actin-dsRed expression were transplanted after 
sublethal irradiation. The irradiation was necessary since the b-actin-dsRed MLL-AF9+ AML 
cells were originally generated by retroviral transduction to GMP cells (Hartwell et al., 2013) 
while the non-dsred MLL-AF9+ AML cells were generated in BM KIT+ cells (Somervaille 
and Cleary, 2006). 
 
4.11 CO-CULTURE BETWEEN HEMATOPOIETIC CELLS AND MSPCS  
For evaluating interaction between HSPC or MLL-AF9+ AML cells and specific mesenchymal 
niche cells, co-culture was performed in normoxic condition and followed up by in vitro 
hematopoiesis assay. For co-culture MSC with HSPC (Paper I & IV) or MLL-AF9+ AML 
cells (Paper III & IV), MSCs were pre-plated to form feeder layer and allow for complete 
coverage of well plate.  
Since the purpose of co-culture was to evaluate mesenchymal niche function to support 
hematopoietic cells, the co-culture was performed in serum-free medium with limited growth 
factors (M5300, supplemented with 10-6M hydrocortisone and penicillin streptomycin) to 
prevent growth competition between MSCs or MPCs and hematopoietic cells. In co-culture 
between MLL-AF9+ AML cells and MSC, 1ng/mL IL-3 was added to maintain MLL-AF9+ 
AML growth while 5-10ng/mL IL-3 was used when MSC was not applied. After the co-
culture, Colony Forming Unit-Cell (CFU-C) or FACS analysis was performed to evaluate 




4.12 COLONY FORMING UNIT CELL (CFU-C) ASSAY  
CFU-C assays was performed in semisolid medium (methocultTM GF M3434) allowing spatial 
isolation of a single HSPC cell (Paper I & IV) or LT-HSC (Paper IV) to clonally expand and 
form different myeloid colonies. The M3434 medium contains IL-3, IL-6, EPO, and SCF to 
promote generation of CFU-Granulocyte Monocyte (CFU-GM) and Granulocyte, Monocyte 
and Erythrocyte (CFU-GME). For visualizing ´erythroid colonies, staining of haemoglobin 
with 2,7 diaminofluorene (DAF) was performed (McGuckin et al., 2003)  
 
4.13 COBBLESTONE AREA FORMING CELL (CAFC) ASSAY 
CAFC is an assay used to evaluate frequency of HSPC based on number of CAFC formation 
beneath stroma cells in vitro (Phloemacher 1989). The assay was performed by platting total 
MSC or different subtype of MSCs (Ebf2+ and Ebf2-PaS) to cover well surface. Once all 
surface area was covered, small number of hematopoietic cells were plated (150 – 250 LSK 
or 300 MLL-AF9+ cells). The CAFC was usually performed at 32-35°C for 14 to 21 days. 
Each CAFC is defined as a colony consists of at least 3 cells beneath stromal cells. In paper 
III and IV, CAFC assays were performed to evaluate MSC function for supporting MLL-
AF9+ AML cell growth as well as providing chemoprotection. it is worth mentioning that 
CAFC from AML cells should be counted no later than 10 days since AML cells grow much 
faster and aggressively. On the contrary, the CAFC from HSPCs takes longer time to form, 
thus should be counted at later time points, up to 2-3 weeks.   
Differ from original methods where heterogenous stromal cell population was seeded, we here 
have used FACS-isolated MSCs in order to specifically evaluate the role of MSC in supporting 
normal HSPC or AML cells. Moreover, by combining prospectively isolated different MSC 
population (a highly enriched MSC (Ebf2+) and Ebf2-MSC (PaS)) and CAFC method, this 
assay could be employed as high-fidelity tool for evaluating interactions between normal and 
malignant stem cells with specific MSC fraction, and the underlying molecular mechanisms. 
 
4.14 MITOCHONDRIA TRANSFER  
To evaluate Lama4-/- MSC chemoprotective function, mitochondria transfer assay was 
performed in paper III. Firstly, the MSCs were labeled with MitoTrackerTMGreen. In order 
to remove unbound probe, the MSCs were washed and incubated for 3-4 hours prior to seeding 
the MLL-AF9+ cells. The frequency of MLL-AF9+ AML cell receiving mitochondria from 
MSC was detected by FACS while the localization of mitochondria in AML cells was 




4.15 MOLECULAR PROFILING & GENE EXPRESSION ANALYSIS OF RARE 
CELL POPULATIONS  
The molecular profiling was evaluated on freshly sorted niche cells including MSCs and 
MPCs. The cells were sorted directly into lysis buffer and kept in -80°C prior RNA extraction 
which was performed prior cDNA synthesis by RT-PCR. The cDNA was then used for qPCR 
or subjected to library preparation prior RNA-sequencing (RNAseq). 
4.15.1 RNAseq  
The purpose of RNAseq in the present study was to provide transcriptomic profile among 
different niche cell populations. The RNAseq procedure consisted of (1) RNA extraction and 
library preparation where cDNA fragments were tagged with adaptors, (2) sequencing with a 
high throughput platform, (3) data analysis.  During RNAseq data analysis, the generated 
sequences were mapped and counted. After normalizing the mapped counts, the differentially 
expressed genes (DEGs) were defined. For Gene Set Enrichment Analysis (GSEA), GSEA 
(v4.0.3) platform were used to identify enriched genes in tested cell population based on 
multiple molecular gene sets included in gene ontology, hallmark and KEGG databases 
(Paper III & IV). When P value < 0.05 and FDR < 0.25, the gene sets were considered 
significantly enriched. 
4.15.2 qPCR with limited materials 
qPCR was performed in paper I-IV to validate finding from RNA sequencing and evaluate 
relative expression of genes related to MSC characteristics, hematopoiesis and inflammatory. 
The qPCR reaction captures the FAM signals generated from amplified gene during 
exponential phase in real time. The house keeping gene (Hprt) of each cell population was 
included in every qPCR experiment. To calculate relative expression of target gene to Hprt, 
the DCT method (2^(CTtarget gene – CTHprt)) was used. 
 
4.16 STATISTICAL ANALYSIS  
Justification of statistical test was based on generated hypothesis prior the experiment. 
Following data generation, the data distributions were tested prior to selecting statistical 
interference (parametric or non-parametric test). All tests for data distribution and statistical 
interference was performed with GraphPad Prism. P-value < 0.05 is considered significant. 
 
4.17 ETHICAL CONSIDERATION 
All experiments were performed in compliance to approved ethical permit (animal study: S40-
14 and 1869, and for human materials: 2012/4:10, 2013/3:1 and 2013/1248-31/4). For animal 
studies, the 3R (Replacement, Reduction and Refinement) was always considered. In 
compliance to Replacement, in vitro assay had been put as first choice in pilot study whenever 
it was possible prior moving to in vivo animal study. To reduce the use of animal (Reduction), 
the present study allocated the total use of animal efficiently and effectively.  
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One way to achieve it was by thoroughly discussing each experiment protocol within all group 
members to prevent unnecessary pitfalls that may impact in increased animal number. To 
comply with Refinement, each procedure related to animal handling was performed only by 
trained persons while animal husbandry was taken care by experienced and trained staff at KI 
animal facility. To reduce suffering of the mice, we always terminated the mice that were in 
severe health conditions defined by local ethical committee and institution in conformity with 
our ethical approvals.  Animals were maintained at ad libitium state and monitored regularly. 
Prior conducting experiment procedure at KI animal facility, the experiment protocols were 
presented to the animal facility staff who provided feedback and technical expertise for 
minimizing harm to the animal. For experiment where patient samples were included (Paper 




5.1 PAPER I: SIPA1 DEFICIENCY–INDUCED BONE MARROW NICHE 
ALTERATIONS LEAD TO THE INITIATION OF MYELOPROLIFERATIVE 
NEOPLASM 
Sipa1 gene deleted mice (Sipa1-/-) develop CML-like disease in an age-dependent manner 
(Ishida et al., 2003; Kometani et al., 2006). These findings suggest an important role of Sipa1 
in the development of MPN. However, it remained unclear whether the MDS/MPN 
development in the aged Sipa1-/- mice was due to the intrinsic loss of Sipa1 in hematopoietic 
cells or in BM niche via non-autonomous manner. In paper I, this question is addressed.  
Sipa1 is reported to be expressed in HSPCs and lymphocytes (Ishida et al., 2003; Kurachi et 
al., 1997) while the expression of Sipa1 in BM marrow niche cells was unknown. To explore 
the impact of Sipa1 loss on BM niche, we firstly examined Sipa1 expression in BM 
mesenchymal niche including MSC and MPC. The freshly sorted BM MSC and MPC from 
mice and human expressed Sipa1 as well as CD31+ endothelial cells. Interestingly, SIPA1 
expression in BM MSCs and ECs was decreased in patients with MPN (CML and CNL). 
Similar but not identical to previous findings, most of the aged Sipa1-/- mice (>16 months old) 
showed MDS/MPN phenotypes as manifested by increased white blood cell (WBC), 
granulocytes (CD11B+GR1+) and neutrophils in peripheral blood, anemia, thrombocytopenia, 
splenomegaly and Mk dysplasia in BM. The BM niche composition of the aged Sipa1-/- mice 
was altered with reduced frequency of BM MSC but increased MPCs compared to age-matched 
Sipa1+/+ mice. Functionally, the ability of Sipa1-/- BM MSCs to differentiate toward osteogenic 
in vitro was impaired in aged Sipa1-/- mice. These data showed alterations of the BM 
mesenchymal niche in MDS/MPN mice. However, it remained to be investigated whether 
the disease was caused by the niche alteration or was induced by the malignant 
hematopoietic cells. 
To address this, we analyzed the BM niche in young adult Sipa1-/- mice (2-3 months old), prior 
to the onset of MDS/MPN. We found the frequency of BM MSC and MPC were increased in 
young Sipa1-/- mice. Furthermore, BM MSCs from young Sipa1-/- mice displayed impaired 
osteogenic but enhanced adipogenic differentiation potency. In line with reduced osteogenic 
potency in vitro, CT scan indicated reduced femoral bone volume in young Sipa1-/- mice. 
Functionally, the young Sipa1-/- BM MSC and MPC displayed higher potency to support HSPC 
growth and promoted them to form CFU-GM, but less in CFU-GME formation in-vitro. 
Molecularly, RNA sequencing revealed upregulation of inflammatory related genes such as Il-
6 and TGF-b in Sipa1-/- BM MSCs and downregulation of genes critical for the maintenance 
of HSCs (Cxcl12, Kitl and Angptl1) in Sipa1-/- BM MSCs and MPCs, providing molecular basis 
of the altered supportive function for HSPCs.  Surprisingly, transplantation of young Sipa1-/- 
BM CD45+ hematopoietic cells to lethally irradiated Sipa1+/+ recipient mice failed to 
recapitulate the hematological disorders observed in the aged Sipa1-/- mice. These findings 
indicated that the development of MDS/MPN in the Sipa1-/- mice was not due to the loss of 




To test whether the development of the disease was caused by Sipa1 loss-induced BM niche 
alterations, the BM CD45+ cell isolated from young Sipa1+/+ was transplanted to either sub-
lethally or lethally irradiated young Sipa1-/- mice. We found that normal Sipa1+/+ BM CD45+ 
cells from young adult mice were transformed into malignant cells in the Sipa1-/- recipients, 
resulting in dyserythropoiesis and increased donor-derived HSPC, GMP and MEP count in 
BM which resembled the MDS/MPN phenotype based on Bethseda proposal (Kogan et al., 
2002). The higher frequency of MEPs was also observed in BM and spleen of lethally 
irradiated young Sipa1-/- recipient mice. The transformation of the Sipa1+/+ CD45+ cells was 
confirmed by secondary transplantation where the recipient mice (Sipa1+/+) showed MDS-like 
phenotype. Altogether, paper I shows Sipa1 deficient BM niche is an instigator of the 
MDS/MPN development.  
5.2 PAPER II: DISTINCT ROLES OF MESENCHYMAL STEM AND 
PROGENITOR CELLS DURING THE DEVELOPMENT OF ACUTE MYELOID 
LEUKEMIA IN MICE 
Paper II shows that Sipa1-/- niche transforms normal CD45+ cells into malignant myeloid 
resulting in MDS/MPN, suggesting an instructive role of the BM niche during development of 
myeloid malignancies. However, the interplay between mesenchymal niche and malignant 
hematopoietic cells in BM is dynamic and disease stage-specific. Once the malignancy is 
established, the role of BM niche may become permissive or even supportive for the disease. It 
has been reported that AML cells alter BM niche to confer AML cell proliferation and suppress 
host hematopoiesis (Baryawno et al., 2019; Hanoun et al., 2014). Thus, understanding how BM 
niche is modulated during myeloid malignancy is necessary to identify potential target to disrupt 
the supportive signals from niche for AML cell growth.  
In paper II, we investigated specifically how BM niche is remodeled progressively by AML 
cells. At the end stage of AML, the BM niche was altered significantly. The frequency of BM 
MSC, MPC and CD31+ (including CD31+SCA1+ arteriolar EC) were increased in mice 
engrafted with MLL-AF9+ AML. Similar niche alterations were observed in AML xenograft 
mice post transplantation of patient derived AML cells. Furthermore, the differentiation 
potential of BM MSCs toward adipogenic and osteogenic lineages in vitro was enhanced in 
AML mice compared to healthy control mice.  
Molecularly, qPCR on freshly sorted BM MSCs, MPCs and CD31+ cells at different time points 
post AML transplantation revealed dysregulated gene expression in these cellular niches. At the 
end stage of AML, we detected reduced expression of hematopoiesis supportive genes in both 
MSCs and MPCs including Cxcl12, Kitl and Angptl1. On the other hand, Spp1 which is negative 
regulator of hematopoiesis was increased. Increased Il-6 expression level indicated an 
inflammatory BM niche at end stage of AML. Sipa1 expression was also reduced as AML 
developed. Elevated expression of Lama4 and Lama5 in AML BM MSCs and MPCs were 





Notably, similar to the frequency of BM niche cells that increased in an AML burden 
dependent manner, the alteration of hematopoiesis-supportive genes in BM MPC also 
correlated with AML burden/progression, emphasizing the remodeling effects of AML cells 
on the niche composition and its subsequent impact on the AML progression. Taken together, 
these data provide evidence for the dynamic molecular interplay between AML cells and 
their BM niche although the functional consequences remain to be validated. 
Our previous study reports that BM MSCs contain a more primitive MSC, marked by Ebf2 
expression. In order to investigate the specific role of BM MSCs during AML development, 
we first analyzed the Ebf2+ cells in the mice post injection of MLL-AF9+ AML into 
immunocompetent Ebf2-Egfp transgenic reporter mouse model. Similar to finding from total 
BM MSC, frequency of the Ebf2+ cell was increased at the end stage of AML. However, the 
Ebf2+ cells were altered to become more differentiated toward MPCs. The role of BM Ebf2+ 
MSC in the formation of leukemic mice was then assessed by lineage tracing strategy using 
Ebf2 triple transgenic mouse (Ebf2-Egfp x Ebf2-CreERT2 x Rosa26loxpStoploxpTomato).  In this 
setup, Ebf2+ cells were reported as GFP+Tomato+ and their progeny will be permanently 
labelled by Tomato expression (GFP-Tomato+) post Cre activation by tamoxifen injection. The 
contribution of Ebf2+ cells to the leukemia niche formation was assessed by the presence of 
the progeny of Ebf2+ cells (GFP-Tomato+) post AML cell injection.  
The progeny of BM Ebf2+ cells that have lost Ebf2 expression (GFP-Tomato+) were found to 
constitute a major part of the mesenchymal niche cells including Ebf2-MSCs, MPCs and 
CD44+ cells. The frequency of the GFP-Tomato+ cell was increased at end stage of AML. 
Majority of the GFP-Tomato+ cells were Ebf2-MSCs and MPCs, which, in consistent with 
earlier observation, were increased post symptomatic onset of AML. This finding revealed that 
the Ebf2+ cells contributed to the formation of leukemic niche in the BM by generating 
different BM mesenchymal niche cells during AML development.  
To further evaluate the functional contribution of BM Ebf2+ cells to AML development, the 
Ebf2-CreERT2X Rosa26-DTA transgenic mice were employed to allow selective Ebf2+ cell 
depletion before or after the MLL-AF9+ AML injection. Surprisingly, loss of Ebf2+ cell did 
not result in the delayed AML onset. On the contrary, the AML development in Ebf2+ depleted 
mice was accelerated. Since host hematopoiesis is known to be impaired along with AML 
progression due to a massive growth advantage of AML cells, we then tested whether the 
deletion of Ebf2+ cells resulted in a greater loss of host HSPCs, which is directly linked to 
AML progression. Indeed, frequencies of LT-HSC, LSK, Pre-MegE, pre-CFU-E, MkP, GMP 
and preGM were drastically reduced in BM of the Ebf2+ cell depleted mice. Concomitantly, 
the frequencies of AML and AML LSC (KIT+) cells were increased.  
In summary, the dynamic interplay between AML cells and BM mesenchymal niche 
resulted in alterations of BM MSC and MPC composition and functions. The AML cells 
educated BM Ebf2+ MSCs to form leukemic niches which in turn promoted AML growth 




5.3 PAPER III: CRITICAL ROLE OF LAMININ a4 FOR HEMATOPOIESIS 
REGENERATION UNDER IRRADIATION-INDUCED STRESS AND ACUTE 
MYELOID LEUKEMIA 
Although our studies in Paper II and others (Hoggatt et al., 2016) demonstrated the remodeling 
effects on BM niche by AML cells, the molecular pathways mediating the effects of the altered 
niche on AML cells and normal hematopoiesis maintenance remain largely unexplored. To 
this end, we have in paper III explored the role of ECM protein laminin a4 (Lama4) in 
hematopoiesis regeneration during myelosuppression and AML progression including 
AML cell response to drug treatment.  
Paper II showed that Laminin a4 (Lama4) expression was elevated in BM MSCs and MPCs 
from mice with AML. This prompted us to study the functional consequence of the Lama4 
upregulation during AML development. Data mining from AML patient in Prognoscan 
(Raponi et al. 2007) suggested an inverse correlation of LAMA4 expression with patient 
survival. Thus, we hypothesized that Lama4 could play a role in AML development either by 
maintaining normal hematopoiesis or inhibiting AML proliferation or both. This hypothesis 
was tested by using Lama4-/- mice (Tyboll et al. 2002) and MLL-AF9 AML mouse model 
established in Paper II.   
At steady state, the impact of Lama4 on blood lineage production and early hematopoiesis was 
mild. However, the hematopoiesis regeneration was significantly impaired in Lama4-/- mice 
post irradiation-induced myelosuppression. Compared to Lama4+/+ mice, the regeneration of 
erythropoiesis, myelopoiesis and megakaryopoiesis were impaired and delayed in Lama4-/- 
mice post-irradiation.  
Since Lama4 is distributed in the basement membrane of endothelial cells (Tyboll et al. 2002) 
and megakaryopoiesis is regulated through direct interactions between Mks and ECs (Dhanjal 
et al. 2007; Junt et al., 2007; Rafii et al., 1995), we further evaluated distribution of Mks at the 
vascular site of the BM. Six weeks after irradiation, Lama4-/- mice had reduced number of Mk 
adjacent to sinusoidal vessels in BM. Additionally, the vessel density was also reduced in 
Lama4-/- mouse BM. These results provided possible mechanisms underlying the impaired 
hematopoiesis recovery, including potential impaired Mk transendothelial protrusion and 
maturation into platelet after irradiation, which in turn could lead to reduced platelet 
production.  
To further explore the cellular mechanisms behind the impaired hematopoiesis, we 
characterized BM mesenchymal niche in Lama4-/- mice. At steady state, the frequency of 
Lama4-/- MPC was reduced in BM while the MSC frequency was not changed. The MPCs 
were then sorted from mouse Lama4+/+ and Lama4-/- BM post-irradiation for RNA 
sequencing. Besides upregulated inflammatory related genes (Tgfb, Il18, Il7d) in the Lama4-/- 
MPCs, GSEA analysis revealed enriched genes associated with OXPHOS (oxidative 





Leukemia represents a severe hematopoietic insult where normal hematopioiesis is 
progressively lost while leukemic cells are massively proliferated. Both processes are closely 
linked, as illustrated by exponential growth of AML cells in paper II. The critical role of Lama4 
for AML progression was studied by transplanting MLL-AF9 cells into Lama4-/- mice.  The 
development of AML in Lama4-/- mice was faster compared to Lama4+/+ mice, demonstrated 
by the reduced survival time of the Lama4-/- mice and the higher frequency of AML LSC in 
BM and PB of Lama4-/- mice. Concomitantly, the platelets (PLTs) were further reduced in 
Lama4-/- mice. In order to evaluate Lama4 role in AML relapse, we treated the Lama4+/+ and 
Lama4-/- AML mice with BM transplantation following lethal irradiation to eliminated AML 
cells. The AML relapsed faster in Lama4-/- mice which was associated with reduced survival 
of Lama4-/- mice.  
The chemoprotective function of the Lama4-/- niche for AML LSCs was evaluated by CAFC 
assay in vitro and in vivo treatment of AML by chemotherapy Ara-C. The higher frequency of 
CAFC reflecting AML LSCs from AML co-cultured with Lama4-/- MSC showed an enhanced 
supportive function of Lama4-/- MSC for AML LSCs. The increased number of residual 
CAFCs and AML LSCs (KIT+) from AML cells cultured with Lama4-/- MSCs post Ara-C 
indicated a higher chemoprotective function of the Lama4-/- MSCs. Consistent with in vitro 
data, 1 day after Ara-C last injection, chemoresistant AML cells were found to be higher in 
spleen and BM of Lama4-/- mice. In addition, the AML cells in Lama4-/- mice had lower ROS 
compared to that in Lama4+/+ mice, suggesting a possible enhanced metabolic support from 
Lama4-/- niche for AML cells to detoxify oxidative stress induced by massive AML cell 
proliferation and the sublethal irradiation.  
Mitochondria transfer has been reported as mechanism provided by niche for acute 
lymphoblastic leukemia chemoprotection (Burt et al. 2019). We then evaluated the 
mitochondria transfer from pre-labeled Lama4-/- MSC to AML cells in vitro. Both Lama4+/+ 
and Lama4-/- MSC did transfer their mitochondria to AML, however, the transfer from Lama4-
/- MSC into the AML was more pronounced during Ara-C treatment. Taken together, the 
findings in paper III shows (1) role of Lama4 in hematopoiesis regeneration after 
irradiation stress, in particular, in erythropoiesis and megakaryopoiesis. (2) The Lama4-
/- mesenchymal niche promotes AML cell proliferation and provides enhanced 
chemoprotection for AML LSCs by transferring mitochondria to AML cells. 
Nevertheless, more work is required to investigate the specific effect of the transferred 
mitochondria in AML cells for their survival during chemotherapy by using inhibitors 
to block mitochondrial transfer. Altogether, these findings from this study suggest that 
activation of LAMA4-receptor signaling pathway could potentially reduce niche 





5.4 PAPER IV : NOVEL CHARACTERISTICS OF SKIN MESENCHYMAL STEM 
CELL AND ITS FUNCTION IN NORMAL HEMATOPOIESIS AND ACUTE 
MYELOID LEUKEMIA 
Besides BM, it has been reported that extramedullary organ acts as reservoir of chemoresistant 
leukemic cells (Ye et al., 2016). However, whether the mesenchymal niche in extramedullary 
organ contributes to AML survival is not known. The existence of mesenchymal-like 
population has been reported in skin tissue (Toma et al. 2001; Vanculik et al. 2012). The cells 
were defined based on retrospective characterization, which entails further questions whether 
skin MSCs are physiologically similar to BM MSCs in supporting normal hematopoietic cells 
and AML cells. 
One of the important findings in paper IV is the characteristic of skin MSC in vivo. By 
employing Ebf2-Egfp transgenic mice, the presence of skin MSC was shown. Similar to the 
BM, skin Ebf2+ cells were highly enriched with MSCs, demonstrated by single cell colony 
assay, multilineage differentiation and serial replating in vitro. Different from BM MSC, skin 
Ebf2+ cells have little potency to differentiate towards chondrogenic in vitro, which was 
supported by lower expression of the genes associated with chondrogenesis, revealed by RNA 
sequencing. Nevertheless, ability to undergo positive osteogenic and adipogenic 
differentiation (bilineage) could be recapitulated. A small fraction of skin MSCs did not 
express Ebf2, but positive for CD140A and SCA1 (Ebf2-MSC (PaS)). The skin Ebf2+ cells 
were located at perivascular site with a high expression of pericyte markers aSMA, NG2 and 
PDGFRb.  
Our lineage tracing experiments using Ebf2 triple transgenic mice (Ebf2-Egfp x Ebf2-CreERT2 
x Rosa26loxpStoploxp-Tomato) revealed the hierarchical relationship between skin Ebf2+ cells 
and Ebf2-PaS MSCs. The Ebf2-PaS MSCs were generated from skin Ebf2+ cells, but not vice 
versa. Besides, the Ebf2+ cells also generated MPC lacking SCA1 expression although major 
fraction of skin Ebf2+ cell progeny was Ebf2-PaS MSCs. While the frequency of skin Ebf2+ 
progeny (Tomato+ cells) was increased, Ebf2+ frequency remained constant for up to 12 
months, providing evidence for the self-renewal properties of skin Ebf2+ cells. Taken together, 
the lineage tracing demonstrated that skin Ebf2+ cells were more primitive during MSC 
developmental hierarchy and that generated downstream mesenchymal cells in skin, as 
reported in BM (paper II).  
The molecular profiles of skin MSC subsets were then determined by RNA sequencing and 
compared with their BM counterparts. Both skin MSCs (Ebf2+ and Ebf2-PaS) expressed 
hematopoiesis supportive niche genes (Angptl1, Cxcl14 and Cxcl12) as similar as that in BM 
MSCs, indicating skin MSCs may also support hematopoiesis and leukemia. Formation of 
similar numbers of CAFC from HSPC co-cultured with skin MSCs to that with BM MSCs 
corroborated robust hematopoiesis supportive function of skin Ebf2+ and Ebf2-PaS in vitro. 
The potential role of skin MSCs for supporting AML cells was suggested by massive MLL-
AF9+ AML cells that infiltrated into the dorsal skin tissue and altered numbers of the skin 
Ebf2+ cells in the skin tissue from the mice that developed AML. 
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In consistent with BM, the frequency of skin arteriole (CD31+SCA1+) increased suggesting 
AML cells also modulated skin mesenchymal niche. Skin MSC supportive function for AML 
LSC was demonstrated by similar number of CAFCs derived from AML cells co-cultured with 
skin MSC subsets as observed in BM MSCs in CAFC assays.  
To test whether skin MSC also have chemoprotective function for AML LSCs, we firstly 
performed AML CAFC assays in the presence of Ara-C. In contrast to the efficient killing of 
AML cells in culture without MSCs, similar numbers of remaining CAFCs from AML were 
observed in the cocultures with skin MSC subsets and BM MSCs. Additionally, frequency of 
AML LSC (KIT+) was maintained equally by both skin MSC subsets, indicating skin MSC 
could provide chemoprotection for resistant AML LSCs. In order to evaluate the in vivo role 
of skin as extramedullary organ with a chemoprotective function, we employed AML-
promoting Lama4-/- mice as a model to study AML chemoresistance. Consistent with in vitro 
findings, dorsal skin of Lama4-/- mice harbored more residual AML cells compared to 
Lama4+/+ mice. Interestingly, the frequency of phenotypically defined chemoresistant AML 
LSC (CD36+) was found to be higher in Lama4-/- dorsal skin post Ara-C treatment, 
emphasizing the role of dorsal skin as a potential reservoir of residual AML cells. 
In summary, paper IV reports (1) the skin MSC compartment consists of Ebf2+ and 
Ebf2-PaS MSCs with similar features as their BM MSC counterparts. The skin Ebf2+ 
cells are more primitive MSCs and can generate more differentiated Ebf2-PaS (MSCs). 
(2) Skin MSCs display similar HSC- and AML-supportive function, as BM MSCs in 
vitro. (3) Skin mesenchymal niche may act as extramedullary reservoir of AML cells and 
protect them from chemotherapy. 
Taken together the findings from Paper I-IV, the present study shows the role of the BM niche 
for the initiation and progression of myeloid malignancies in mice. During this AML 
progression, LAMA4 is required for maintaining BM niche homeostasis and suppressing 
AML progression during development and drug treatment. In addition, the mesenchymal cell 
niche in skin tissue may contribute to AML maintenance during chemotherapy. However, 








6.1 INSTRUCTIVE ROLE OF BM NICHE IN THE INITIATION OF MYELOID 
MALIGNANCIES (MDS/MPN) 
In paper I, we have studied the role of the BM niche in MDS/MPN development using Sipa1-
/- mice that develop age-dependent MPN. The majority of the aged (16month old) Sipa1-/- mice 
showed a MDS/MPN phenotype. The disease phenotype did not completely resemble previous 
report (Ishida et al., 2003; Kometani et al., 2006) where majority of the mice developed CML-
like MPN at the age of 12months and beyond. This discrepancy might be due to different 
genetic background and housing environment. By prospectively characterizing BM niche in 
the Sipa1-/- mice at different time points, we have showed that deletion of Sipa1 resulted in 
phenotypic and molecular alterations of BM cellular niches including MSCs and MPCs prior 
to the onset of the disease, suggesting possible involvement of the altered Sipa1-/- niche in the 
initiation of the MDS/MPN. This possibility was validated by the development of MDS/MPN 
after transplantation of normal hematopoietic cells into the Sipa1-/- host mice. It is necessary to 
note that no hematopoiesis defects were detected in reciprocal transplantation of Sipa1 deficient 
hematopoietic cells into wild type mice, showing Sipa1 deficiency in hematopoietic cells did 
not lead to malignant transformation.  
Proinflammatory niche and impaired hematopoiesis supportive functions are hallmarks of 
myeloid neoplasms (Arranz et al., 2014; Baryawno et al., 2019; Dong et al., 2016; Schepers et 
al., 2013). In line with this, the BM MSCs from young Sipa1-/- mice had elevated genes related 
to inflammatory cytokines (Il6, Tgfb1). Additionally, the finding of elevated Thpo in young 
Sipa1-/- MPCs was consistent with previous report (Schepers et al., 2013) showing increased 
THPO in BM plasma of BCR-ABL1 MPN mice. Furthermore, a higher Thpo expression might 
contribute to the increased granulopoiesis, Mk dysplasia and enhanced MEPs in Sipa1-/- mice. 
The impaired hematopoiesis supportive function of Sipa1-/- MSCs and MPCs were 
demonstrated by reduced ability of the niche cells to support HSPCs (LSK cells) to generate 
CFU-GME meanwhile enhanced capacity to form myeloid colonies (CFU-GM). The 
functional alterations were supported by the downregulation of the key HSC regulators such as 
Cxcl12, Angptl1 and Kitl in both MSC and MPC. Altogether, paper I provides new evidence 
for abnormal niche-driven MDS/MPN.  
These findings together with the SIPA1 downregulation in BM MSC and CD31+ cells isolated 
from MPN patients meriting future study to investigate the prognostic value of SIPA1 
expression in BM niche in MPN patients who undergo allogenic HSC transplantation. 
Furthermore, delineating exact niche cell type or its anatomical distribution in Sipa1 deficient 
mice that specifically contribute to MDS/MPN development would facilitate to identify the 




6.2 NICHE-REMODELING BY LEUKEMIA AND BM NICHE CONTRIBUTION TO 
AML PROGRESSION  
In paper II, we report BM niche remodeling by MLL-AF9+ AML cells and the cellular and 
molecular mechanisms involved in the leukemic niche for AML progression in mice. The 
frequency of BM MSC, MPC, CD31+ were increased in AML burden dependent manner. The 
BM MSCs from AML mice had enhanced the osteogenic and adipogenic potency. The 
dynamic remodeling also occurred molecularly, in particular, in MPCs where expression of 
hematopoiesis niche genes such as Cxcl12, Angptl, Nov, and Igf1 (Arai et al., 2004; Greenbaum 
et al., 2013; Gupta et al., 2007; Omatsu et al., 2010; Thoren et al., 2008) were reduced as AML 
burden increased. On the other hand, the expression of inflammatory gene (Il6) in BM MSC 
and MPC were enhanced in correlation to AML burden. While loss of hematopoiesis function 
and high pro-inflammatory cytokines have been reported (Baryawno et al., 2019; Hanoun et 
al., 2014), our findings provide additional evidence for molecular alterations in BM niche from 
AML mice. The functional consequence of the alterations should be studied in the future. 
Our previous study has shown BM Ebf2+ cells mark primitive MSC populations and generate 
Ebf2- cells in vitro (Qian et al., 2013). In paper II, we examined the specific role of BM Ebf2+ 
cells during AML development. By performing in vivo lineage-tracing of Ebf2+ cells, we 
demonstrated the contribution of BM Ebf2+ cells in the formation of AML niche. The BM 
Ebf2+ cells generated different progenies that lost Ebf2 expression and consisted of less 
primitive Ebf2-MSCs, MPCs and CD44+ mature stromal cells in the AML niche as AML 
progressed. The Ebf2+ cells were also altered by AML cells to undergo lineage bias toward 
more differentiated MPC, which resulted in the imbalance of primitive MSC and more 
differentiated MPC in the BM. Thus, depletion of Ebf2+ cells may amplify this lineage 
imbalance resulting in even more dramatic niche reconstruction and greater loss of host HSPC 
facilitated the faster AML development.  
During AML development, Sipa1 expression in BM MSCs and MPCs was also downregulated 
at end stage of AML. This is particularly interesting since we showed in paper I that loss of 
Sipa1 in BM niche drove MDS/MPN development. In line with this finding the reduced Sipa1 
expression in BM niche may contribute to AML progression. In addition, we here report the 
increased Lama4 and Lama5 expression in BM MSCs and MPCs in AML mice, suggesting 
BM ECM was also remodeled by AML cells. The LAMA4 and LAMA5 are active chains of 
several laminin isoforms (Laminin-411/421, laminin-511/521), respectively to form cell-
binding domains. The binding between laminin and HSC has been reported to play a critical 
role in HSC homing and engraftment (Qian et al., 2007; Qian et al., 2006). Moreover, in a 
mouse study where CML cell proliferation was promoted, Lama4 expression was elevated. 




6.3 THE ROLE OF LAMA4 IN THE BM NICHE FOR HEMATOPOIESIS 
REGENERATION AND AML PROGRESSION  
In paper III, we studied the role of Lama4 gene encoding one of BM ECM (Scheele et al., 
2007; Susek et al., 2018) in hematopoiesis recovery under hematopoiesis insults including 
irradiation and AML. Following irradiation, Lama4-/- mice displayed impaired recovery of 
RBC, HGB and PLTs in PB. Furthermore, the Lama4-/- mice had rapid regeneration of MEP 
while GMP and MkP were slowly recover in BM, showing the important role of Lama4 in 
erythropoiesis and megakaryopoiesis. Following AML-induced hematopoiesis insult, PLT 
impairment was more pronounced and host hematopoiesis disruption became more severe, 
emphasizing the important role of Lama4 for hematopoiesis maintenance and AML 
progression. 
Mechanistically, Lama4-/- mice had lower frequency of ECs and MPCs in the BM. Moreover, 
the Lama4-/- MPC displayed reduced expression of Angpt1, Cxcl10, Fn1, Nid1, and 
upregulation of negative regulators of hematopoiesis, such as Osteopontin (Spp1) (Nilson et 
al. 2015, Stier et al. 2005), other inflammatory genes (Tgfb, Il17d and Il18) and genes related 
to OXPHOS activity. These molecular alterations could further cause hematopoiesis 
regeneration defects under stress following irradiation.  
 
6.4 LAMA4 IN THE BM NICHE INHIBITS AML DEVELOPMENT AND LOSS OF 
LAMA4 PROMOTES CHEMOPROTECTIVE FUNCTION OF BM NICHE FOR AML 
LSC VIA INCREASED MITOCHONDRIA TRANSFER  
In paper II we have shown that Lama4 was upregulated in BM MSCs and MPCs in AML 
mice. However, the functional impact of Lama4 in BM niche for AML progression was not 
known. To this end, in paper III we evaluated the role of Lama4 during AML development.  
The Lama4-/- mice developed AML faster and maintained higher frequency of AML LSC in 
BM, compared to Lama4+/+ mice.  CAFC assay further demonstrated the enhanced ability of 
Lama4-/- MSCs to maintain AML LSCs, pointing to the inhibitory role of Lama4 in AML 
development.  
BM MSPCs have been reported to provide chemoprotection for AML LSCs via mitochondria 
transfer (Forte et al., 2020). Our in vitro AML CAFC assays demonstrated similar finding as 
MSC transferred mitochondria to AML cells. In addition to that, we showed increased 
mitochondria transfer from Lama4-/- MSCs to AML in presence of Ara-C. Future studies to 
profile the mitochondria activity in Lama4-/- MSC will be necessary to elucidate the critical 
factors in Lama4-/- MSC mitochondria that contribute to AML LSC salvage. Altogether, paper 
III reports that loss of Lama4 enhances niche chemoprotection for AML LSCs via 
mitochondria transfer, thus, Lama4 in BM niche may inhibit AML development by 




6.5   CHARACTERISTICS OF MSC IN EXTRAMEDULLARY SKIN TISSUE AND 
THEIR FUNCTION FOR SUPPORTING NORMAL HEMATOPOIETIC AND AML 
STEM CELLS 
Extramedullary niche for leukemia development and as reservoir of chemoresistant LSC has 
been recognized (Ye et al., 2016). However, the exact contribution of the extramedullary 
niches for hematopoiesis and leukemia have not been well defined due to lack of knowledge 
of the niche cell identity and the secreted factors from the niches. In paper IV, we firstly 
characterized MSC in dorsal skin tissue and evaluated their contribution to AML LSCs. 
We have previously shown that BM Ebf2+ cells are primitive MSCs (Qian et al., 2013) and 
contribute to AML development (Paper II). Similar to BM Ebf2+ cells, skin Ebf2+ cells were 
also highly enriched with MSCs. In dorsal skin, the in vivo lineage tracing data showed skin 
MSCs had a same mesenchymal hierarchy as BM MSCs in which skin Ebf2+ cells seemed to 
reside at the top of the MSC developmental hierarchy and could generate the less primitive 
MSCs (Ebf2- PaS (MSC)) and MPCs. Different from BM MSCs, skin MSCs were enriched 
with genes related to skin regeneration and expressed lower level of genes related to bone 
regeneration, indicating tissue-specific phenotype of MSC from BM and skin. This study 
demonstrates novel characteristics of skin MSCs and provides techniques to prospectively 
isolate native skin MSCs.  
Another novelty in paper IV is the findings of skin MSC hematopoiesis supportive function 
and its chemoprotection on AML LSCs. Molecularly, both skin Ebf2+ and Ebf2- PaS (MSC) 
expressed hematopoiesis supportive genes such as Angptl1, Cxcl12, Kitl, Cxcl14. Lama4 was 
also expressed in skin Ebf2+ and Ebf2- PaS (MSC). The in vitro hematopoiesis functional 
assay supported the molecular profiling as skin Ebf2+ and Ebf2- PaS (MSC) maintained LT-
HSC. Although the assay was in vitro based, the numbers of CAFC and CFU-C showed ability 
of skin MSC to maintain LT-HSC with ability to generate myeloid lineage. Furthermore, 
CAFC number has been shown to correlate with the number of injected HSC in transplantation 
assay (Ploemacher et al., 1989), highlighting high fidelity of our CAFC assay for assessing 
LSC growth in vitro. Nevertheless, the selected in vitro assays limited the evaluation of LT-
HSC potency to generate lymphoid lineage.  
Studies in BM have shown the AML cells receive various supports from MSPC, but whether 
MSPCs in the extramedullary organ display similar function is not known. Here, we reported 
that skin MSC (Ebf2+ and Ebf2- PaS (MSC)) maintained AML cells similarly to BM MSCs. 
Nevertheless, the alteration of skin Ebf2+ cells during AML development was found to be 
different to BM Ebf2+ cells. While BM Ebf2+ cells were increased, the frequency of skin Ebf2+ 
cells were reduced, indicating mesenchymal niche alteration might be unique for AML 
extramedullary mesenchymal niche. Besides maintaining AML cells, the skin Ebf2+ and Ebf2- 
PaS (MSC) also provided chemoprotection for AML cells as did their BM counterpart.  
Using Lama4-/- mice which in paper III was shown to promote chemoresistance of AML LSC, 
we demonstrated dorsal skin acted as extramedullary site where massive AML infiltrated and 
chemoresistant AML LSCs were retained.  
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The possibility of clonal selection within retained chemoresistant AML LSCs in skin needs to 
be further studied. Additionally, the study on interplays between skin MSC and AML cells 




7 CONCLUSIONS  
The thesis work shows the contribution of mesenchymal cell niche to normal hematopoiesis 
maintenance and the development of myeloid malignancies in mice. In paper I, we have 
demonstrated that the loss of Sipa1 induces BM niche alterations which drives the MDS/MPN 
development in Sipa1-/- mice. In paper II, our data show niche-remodeling effect in a 
transplantation-induced AML mouse model and the suppressive role of BM MSCs in AML 
niche formation and the progression of AML. Specifically, the primitive BM MSC (Ebf2+ 
cells) are instructed to generate higher frequency of progenies including more differentiated 
Ebf2-MSCs, MPCs and CD44+ cells. During AML development, depletion of Ebf2+ cells 
accelerates AML onset, showing a suppressive role of the Ebf2 expressing MSCs. The AML 
cells also increased Lama4 expression in BM MSCs and MPCs. However, deletion of Lama4 
in mice accelerates AML progression, shown in paper III.  Mechanistically, loss of Lama4 in 
MSCs promotes AML LSC proliferation and provide chemoprotection via mitochondria 
transfer and modulating antioxidant activity in the AML cells. Further investigation in paper 
IV suggests that increased number of AML cells infiltrated in skin tissue in the lama4 deficient 
mice during AML development and post Ara-C therapy. The skin MSCs share similar 
immunophenotype and stem cell properties, and also display supportive function for normal 
HSCs and chemoresistant AML LSCs, highlighting the previous unrecognized role of 






















8 POINT OF PERSPECTIVE 
Although BM niche contribution to hematopoiesis has been acknowledged, the dynamic roles 
and mechanisms of the niche in leukemia remain poorly understood. The findings in this thesis 
support a notion that the niche function is disease-specific. In paper I, the MDS/MPN 
development in germline deleted Sipa1 mice is driven by the altered BM niches. In this paper, 
the BM niches act as instigator for the development of MDS/MPN, as shown by the 
transplantation of Sipa1+/+ mice to Sipa1-/- recipient mice whose BM niche were already 
altered due to Sipa1 loss. Meanwhile, in paper II, the findings showed BM niche can be 
remodeled by AML cells. Since AML mouse model was generated by injection of MLL-AF9+ 
AML cells to healthy and immunocompetent mice, the remodeling effects of AML cells on 
BM niche was illustrated by the dynamic alteration of BM niche following AML injection. 
The altered niche become more supportive for AML cells but suppressive for host 
hematopoietic cells. Future work should be focusing on identification of the molecular 
pathways mediating the niche-remodeling effects. 
The findings of the role of MSCs and Lama4 during normal hematopoiesis and myeloid 
malignancy provide new insights into future study on the role of these factors in AML in 
patients. Patient derived xenografted mouse model could be a useful tool for the study. 
Restoration of BM niche by modulating MSC proliferation and/or by administering LAMA4 
or activator for Lama4 pathway might be a good strategy to explore the therapeutic possibility 
to treat the leukemia.  
Findings of AML infiltration in skin tissue provide evidence that skin is AML extramedullary 
reservoir. Furthermore, skin MSCs supported and protected AML from Ara-C which triggers 
further research questions on skin MSC contribution to AML relapse. In line with it, another 
follows up study would be evaluating the clinical relevance of our finding in AML mouse 
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